News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

Hainan Boao Hope City Pioneering Unique Medical Policies and Driving Collaboration with Denmark's Biopharmaceutical Industry

Hainan Boao Lecheng International Medical Tourism Pilot Zone

HAINAN, CHINA - Media OutReach - 28 October 2023 - From 12 to 13 October, a delegation from Hainan Province, organised by the Hainan Provincial Government, visited Denmark for a series business events to attract investment and talents. During the events, the first and currently the only special medical zone in China, the Boao Lecheng International Medical Tourism Pilot Zone(Boao Hope City) was featured at the Hainan Free Trade Port Lecheng Denmark Promotion Conference, the delegation also took the opportunity to visit some local pharmaceutical companies and relevant institutions in Denmark, sharing opportunities and showcasing the aspirations to achieve win-win cooperation. Representatives and officials from over 30 renowned international pharmaceutical and medical device companies, such as ALK from Denmark, the Nordic Life Science Partners ApS (NLSP), and the Danish Life Science Cluster, gathered to explore potential collaborations and shared goals in the medical sector between Denmark and the Hainan Free Trade Port at the Promotion Event. The discussions primarily focused on the emerging opportunities and future prospects for cooperation, as well as the specific areas of collaboration within the biopharmaceutical industry. Fruitful conversations were held with the Hainan delegation, fostering meaningful exchanges. The upcoming 2 nd Boao International Conference on Real World Studies of Medical Products, scheduled for the end of October this year, also captured the interest of the attendees. It is estimated that approximately 800 experts, scholars, and executives from domestic and international pharmaceutical regulatory agencies, research institutes, and pharmaceutical companies will participate in the conference. During the event, the Boao Lecheng International Medical Tourism Pilot Zone Administration, the Danish Life Science Cluster, and NLSP came together to sign a strategic cooperation agreement. The agreement aims to foster deeper collaboration in various areas such as healthcare, chronic disease prevention and management, telemedicine, digital health, as well as the introduction of innovative drugs and medical devices. On the following day, the Boao Lecheng International Medical Tourism Pilot Zone Administration, along with representatives from medical institutions in the zone, continued their investment and business activities in Denmark. They actively engaged in exchanges and established connections with Healthcare Denmark, ALK, and other innovative pharmaceutical companies and relevant institutions in Denmark, with the aim of advancing cooperation in the biopharmaceutical industry. Officials from the Hainan Provincial Government acknowledged Denmark's global reputation in the healthcare sector and highlighted the open environment for foreign trade and unique medical policies offered by the Hainan Free Trade Port that could bring benefits to the Boao Hope City. As the benefits and advantages provided by the policies of the Hainan Free Trade Port are gradually becoming evident and accessible and the business environment improves, both Denmark and Hainan can capitalise on their respective strengths to explore substantial opportunities for cooperation in the medical sector. Representatives from Healthcare Denmark acknowledged the thriving development of the Hainan Free Trade Port, which presents multinational pharmaceutical companies with extensive growth prospects. They expressed their dedication to focusing on Hainan and the Boao Hope City, making the most of the distinctive policy benefits and strategic location offered by the Hainan Free Trade Port and the Boao Hope City. They also emphasised their intention to leverage their institutional connections to high-quality medical resources in Denmark to foster deeper cooperation and explore opportunities for development. Hainan the Boao Hope City( http://en.lecityhn.com/ ) has capitalised on the benefits of the "pilot zone" policy and the collaboration with international pharmaceutical and medical device companies. It has forged strong partnerships with more than 170 companies in the pharmaceutical and medical device sectors from over 20 countries and regions. This collaborative effort has facilitated the introduction of over 350 urgently needed imported medical devices for clinical use. Additionally, leveraging the Boao Hope City's real-world evidence-based clinical evaluation, twelve products have successfully obtained registration in the domestic market. As a result, the Boao Hope City has emerged as the primary gateway for international innovative pharmaceutical and medical devices to expedite their entry into the Chinese market. Moving forward, the Boao Hope City will further enhance its commitment to openness and cooperation. It will strengthen collaborations with global pharmaceutical companies and exceptional expert teams, constantly introducing high-quality medical resources and advanced pharmaceuticals into the technologies from around the world. The aim is to expedite the entry of international innovative Chinese market, ultimately benefiting the general public. These efforts will also contribute to positioning the Hainan Free Trade Port as a leading hub for medical innovation in China. Contact Details Chen Xi +86 898 6283 0087 chenxi@lecityhn.com

October 27, 2023 01:58 PM Eastern Daylight Time

Video Image
Article thumbnail News Release

James McDevitt, Head of Equity Sales & Trading at Roberts & Ryan, Inc., is selected by Irish America Magazine for its 26th Annual Wall Street 50

Roberts & Ryan, Inc.

Roberts & Ryan, Inc., America’s first Service-Disabled Veteran-Owned Broker Dealer, is proud to recognize James McDevitt for his selection to Irish America Magazine’s 26th Annual Wall Street 50. The magazine’s Wall Street 50 recognizes the outstanding accomplishments and success of the best and the brightest Irish American and Irish-born leaders of the financial industry. Mr. McDevitt will be honored at the magazine’s gala dinner on Monday, October 30, 2023, at The New York Yacht Club. Jim’s Irish heritage can be traced back to both sets of Grandparents who emigrated to the United States in the late 1920’s. The McDevitt side from County Derry, and the maternal side from County Clare. Ireland and all things Irish have always been highlighted at family events, the history, and the luck that found the family in NYC. Mr. McDevitt is head of Equities Sales & Trading, Capital Markets at Roberts & Ryan, Inc., with an expertise in equity trading. He is a graduate of Oneota State College in New York, where he received his Bachelor of Arts degree, with a focus on American History. He also studied Technical Analysis at the New York Institute of Finance. Jim was a specialist on the floor of the New York Stock Exchange (NYSE) for 25 years, rising to become a partner at MJ Meehan & Co, and then as a Senior Vice President with Bank of America Specialists. During his career, Jim managed the trading post for marquee NYSE listed securities including Citibank, Walmart, Colgate, Sprint, McDonald’s, and JP Morgan. Jim spent three years at Academy Securities as a Managing Director selling fixed income and equity services to Corporate Treasurers. Jim has been involved in a number of charities and is a Board Member of Roberts & Ryan, Inc. He resides in Long Branch, NJ with his wife Nancy. They have three children, Patrick, Jennifer, and Colin. About Roberts and Ryan, Inc. Roberts & Ryan, Inc. is a Service-Disabled Veteran Owned (SDVO) broker dealer providing services in debt and equity capital markets, equity and fixed-income secondary trading, as well as corporate access events. The firm was founded in 1987 by a United States Marine Corps Vietnam combat veteran and Purple Heart recipient. With over $1.8 million in committed donations since 2018, Roberts & Ryan is active in donating to charitable foundations that make significant positive impacts in the lives of veterans and their families, focusing on general wellness, mental health, and career transition. To learn more about Roberts & Ryan, please visit www.roberts-ryan.com. Contact Details Michael C. Del Priore +1 646-859-4061 mdelpriore@roberts-ryan.com Company Website https://www.roberts-ryan.com

October 27, 2023 09:00 AM Eastern Daylight Time

Article thumbnail News Release

Zynex makes Healthcare Technology Report’s Top 100 healthcare tech companies for 2nd straight year

Zynex Medical

Zynex Inc Founder and CEO Thomas Sandgaard joined Steve Darling from Proactive to share news the company has been recognized as one of the Top 100 Healthcare Technology Companies of 2023 by The Healthcare Technology Report. Zynex secured the 23rd spot on the list, marking its second consecutive appearance in the top 100. Sandgaard says this is the second year in a row that Zynex has received recognition in The Healthcare Technology Report's top 100 list. In the previous year, the company was ranked 33rd. Zynex's consistent presence on this prestigious list underscores its ongoing commitment to innovation and excellence in healthcare technology. The company has a focus on pain management and hospital monitoring products. While both divisions are important, the company's primary revenue source lies in pain management, where they've maintained a successful business model for 27 years. Their pain management therapies are side-effect-free and covered by insurance companies, leading to impressive annual revenues, expected to exceed $200 million in the near future. The profitability of the pain management division enables Zynex to fund the development of products in the monitoring division. This financial strength and product diversity attract various types of investors, both retail and institutional. Zynex's recent financial performance has been outstanding, with consistent growth and successful quarterly results, continually surpassing analyst estimates. Zynex's future growth primarily hinges on its pain management division, with significant revenue expected in the coming years. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

October 26, 2023 02:33 PM Eastern Daylight Time

Video
Article thumbnail News Release

Ondine Biomedical’s Steriwave nasal photodisinfection platform now used across Canada

Ondine Biomedical Inc

Ondine Biomedical Inc president and chief technology officer Nicolas Loebel joined Steve Darling from Proactive to share news the company’s Steriwave technology is being implemented at the Queen Elizabeth II Health Sciences Centre in Halifax which is a significant development for infection prevention in orthopedic surgery. The Queen Elizabeth II Health Sciences Centre in Halifax, affiliated with Dalhousie University, has adopted Steriwave, Ondine Biomedical's infection prevention method, for use in orthopedic surgeries. This technology is designed to reduce the risk of post-surgical infections, a critical concern in healthcare settings. The company's research highlights its ability to combat extensively drug-resistant microbes (XDR), an alarming threat to patient safety. Ondine's platform effectively kills these microbes, creating a barrier against antimicrobial resistance. The implementation of Steriwave is particularly crucial as healthcare institutions worldwide grapple with concerns about antimicrobial resistance. The rise of drug-resistant pathogens poses a significant threat, making infection prevention and control paramount in hospitals. Steriwave is now available in hospitals across Canada, including renowned institutions like Vancouver General Hospital, the University of British Columbia, Ottawa hospitals, and the Montreal Heart Institute. This widespread adoption highlights the technology's effectiveness and the growing recognition of its role in reducing healthcare-associated infections. The statistics related to healthcare-associated infections in Canada are concerning. One in nine hospital patients in Canada experiences a healthcare-associated infection, resulting in approximately 12,000 deaths annually. Antibiotic-resistant infections contribute significantly to this mortality rate. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

October 26, 2023 10:31 AM Eastern Daylight Time

Video
Article thumbnail News Release

Kate Hudson Joins Symbiome as Creative Advisor

Symbiome

Symbiome ™, the pioneering microbiome research & development skincare brand announced today that actress and entrepreneur Kate Hudson joined the company as a Creative Advisor. As an avid Symbiome customer, Hudson will join Symbiome’s team of scientists and executives as they develop the next generation of microbiome products in consumer verticals ranging from skin to gut and oral health. Symbiome addresses the root causes of inflammatory disease in global populations, with a core mission to restore health by studying the ancestral human microbiome. With health as the primary design parameter for consumer product development, Symbiome’s eponymous skincare business is the first result of over five years of advanced microbiome research. "Kate and I are both passionate about the importance of the microbiome to our health and well-being,” says Larry Weiss, natural products chemist, Stanford-trained MD, and the CEO and Founder of Symbiome. “We are committed to developing scientifically validated products with the highest standards that help people understand and unlock the potential of the microbiome to improve their health. I am thrilled to welcome Kate to the Symbiome team” “Almost immediately after I started using Symbiome skincare, I could see and feel the difference,” says award-winning actress and entrepreneur Kate Hudson. “I am proud and excited to join the brilliant and dedicated Symbiome team on their mission to improve health from the outside in. I look forward to a future where the products that we love also nourish our microbiome, enhancing our beauty and our health.” About Symbiome. Weiss Bioscience, Inc. is a San Francisco-based microbiome biotechnology company focusing on health and wellness and the developer of the Symbiome ® brand of BioIntact ® fermented skincare products. Weiss Bioscience has sponsored three international academic research expeditions deep into the Amazon rainforest, defining an evolutionary reference point for the human microbiome and transforming our understanding of the healthy microbiome. Symbiome scientists have translated this groundbreaking research into a unique line of proprietary skincare products formulated with naturally fermented Amazonian botanicals to restore what has been lost in the modern world. Symbiome’s skincare lineup includes ten clean, organic, sustainable, and traceable products, all with less than eight ingredients. Learn more about Symbiome, and follow Symbiome on Instagram, LinkedIn, and Facebook. Contact Details BPCM Archita Patel +1 281-725-2121 archita@bpcm.com Company Website https://www.symbiome.com

October 25, 2023 12:00 PM Eastern Daylight Time

Article thumbnail News Release

Centre for Neuro Skills’ Dr. Mark Ashley to Present at American Congress of Rehabilitation Medicine Centennial Conference

Centre for Neuro Skills

Dr. Mark J. Ashley, CEO and Founder of Centre for Neuro Skills (CNS), will be a featured presenter and course speaker at the American Congress of Rehabilitation Medicine’s (ACRM) 100 th Annual Conference, the world’s largest interdisciplinary rehabilitation research event, in Atlanta, GA, from October 30 through November 2. The conference will open with the ACRM Leadership Development Course, a one-day workshop providing tools for effective mentorship and leadership. With more than 40 years of clinical and business leadership experience, Dr. Ashley will present a unique approach to mentoring and offer strategic planning tools for healthcare professionals. As one of four selected plenary presenters, Dr. Ashley will also open day two of the conference with his presentation, “The History, Efficacy, and Potential of Post-Acute Community-Based Rehabilitation for Acquired Brain Injury,” which analyzes the origins and evolution of community-based rehabilitation and explores the potential for this level of treatment. “Every year, about 1.5 million Americans experience a traumatic brain injury,” said Dr. Ashley. “It’s crucial that we continue researching and advancing brain injury rehabilitation and treatment to improve patient care and outcomes. I’m honored to participate in ACRM’s annual conference, collaborating with other rehabilitation providers to promote research that will benefit patients.” *** About Centre for Neuro Skills Centre for Neuro Skills is an experienced and respected world leader in providing intensive rehabilitation and medical programs for those recovering from all types of brain injury. CNS covers a full spectrum of advanced care from residential and assisted living to outpatient/day treatment. Founded by Dr. Mark Ashley in 1980, CNS has seven locations in California and Texas. For more information about Centre for Neuro Skills, visit: www.neuroskills.com, Facebook, Twitter, LinkedIn, YouTube. Media, please note: Visual assets, including photos, are available. To request an interview with CNS leadership or clinical staff, please contact Robin Carr at 415.766.0927 or CNS@landispr.com. # # # Contact Details Landis Communications Inc. Robin Carr +1 415-766-0927 cns@landispr.com Company Website https://www.neuroskills.com/

October 25, 2023 08:01 AM Pacific Daylight Time

Image
Article thumbnail News Release

xCures Partners with the Pancreatic Cancer Action Network (PanCAN)

xCures

xCures, a leader in real-time clinical data technology, is thrilled to announce a pivotal partnership with the Pancreatic Cancer Action Network (PanCAN). As part of the agreement, PanCAN's researchers and grantees will have unparalleled access to xCures' deidentified Real-time, Regulatory-grade Clinical data. This collaboration aims to drive innovations and breakthroughs in pancreatic cancer research by harnessing the power of real-time patient data. xCures database boasts fully longitudinal clinical data from thousands of pancreatic cancer patients, including over 25,000 locations and ~4,000 medical records per patient. The benefits of this partnership extend beyond the research community. xCures is making its xINFORM patient portal available to PanCAN's leading Patient Services program. The state-of-the-art portal aggregates and centralizes patients’ medical records and structures them into a computable format and an easy-to-understand longitudinal timeline. The xINFORM portal supports patients in being matched with suitable treatments and clinical programs, obtaining invaluable second opinions. Sudheer Doss, Ph.D., Chief Business Officer of PanCAN, shared his enthusiasm for the partnership: "We're always in search of innovative ways to serve our patient community better and accelerate pancreatic cancer research. As part of the comprehensive free services we offer through our PanCAN Patient Services program, this platform can pave the way for identifying optimal treatments and ensuring that our patients receive the best care possible." The PanCAN-xCures partnership blends the strengths of both organizations to advance patient outcomes and bolster research capabilities. “We at xCures are deeply committed to placing patients at the forefront of all our endeavors,” said Mika Newton, CEO of xCures. “This new partnership with PanCan is a testament to our dedication to advancing patient-centric solutions and strengthening our bond with patient advocacy organizations. Together, we will usher in a brighter, more hopeful future for all.” About xCures xCures Inc. operates an AI-assisted platform that automatically retrieves medical records from all sites of care. The (unstructured) data is aggregated and organized into a powerful, up-to-date care summary that helps cancer patients get the right therapy at the right time. The platform's portals, xINFORM for patients and xDECIDE for providers, facilitate treatment option decisions. The research portal, xUTILITY, generates Real-time, Regulatory-grade, Clinical data (RRC) for studies and decentralized trials. For more information, contact info@xcures.com or visit http://www.xcures.com. About PanCAN The Pancreatic Cancer Action Network (PanCAN) leads the way in accelerating critical progress for pancreatic cancer patients. PanCAN takes bold action by funding life-saving research, providing personalized patient services and creating a community of supporters and volunteers who will stop at nothing to create a world in which all pancreatic cancer patients will thrive. For 18 years in a row, PanCAN has earned a Four-Star Rating from Charity Navigator – the highest rating an organization can receive. This rating designates PanCAN as an official “Give with Confidence” charity, indicating strong financial health, ongoing accountability and transparency. Contact Details Patrick van der Valk pvandervalk@xcures.com Company Website https://xcures.com

October 25, 2023 10:15 AM Eastern Daylight Time

Article thumbnail News Release

FUZE Technology Acquires MobileQubes Expanding its chargeFUZE network in Transit, Gaming & Healthcare

Full Scope PR

Los Angeles, CA - FUZE Technology (“FUZE”), a distinguished IoT company recognized for seamlessly merging hardware and software technology, has revealed its strategic acquisition of MobileQubes, a pioneering entity in portable charger vending solutions. This acquisition marks a significant expansion of FUZE Technology's network of smart charging stations, firmly establishing it as a leading provider of out-of-home mobile charging solutions across North America. FUZE, operating under its prominent brand chargeFUZE, is already a significant player in the out-of-home mobile charging landscape. Their portfolio includes extensive partnerships with Live Nation Entertainment, Unibail-Rodamco-Westfield (URW), ASM Global, Simon Property Group, and more. FUZE also powers guest experiences for the majority of professional sports organizations in North America, spanning all five major sports leagues. Furthermore, FUZE is a prominent presence at various festivals and large flagship events nationwide, including F1, US Open, Live Nation, Insomniac and C3 events. MobileQubes, widely acknowledged for pioneering portable charger vending, has made remarkable strides in mass transit by securing partnerships with major public transit operators in the US. Their influence also extends into the casino, gaming, and healthcare industries, showcasing their exceptional prowess in portable charging solutions over the past decade and earning them recognition as the original vending solution. Co-Founders Brandon Afari and Ryan Levy expressed their enthusiasm regarding the acquisition, stating, " We are thrilled to welcome MobileQubes into the FUZE family. Their expertise in portable charging and strategic partnerships in transit and gaming perfectly align with our objectives in expanding into IoT and other hardware/software avenues, including the healthcare sector." With this strategic acquisition, FUZE Technology aims to combine its strengths with those of MobileQubes, creating synergies across large-scale distribution verticals that encompass public transit systems, digital out-of-home solutions, and now healthcare. Sean Carrigan, Co-Founder and CEO of MobileQubes, stated, " This merger is a significant step forward for MobileQubes, aligning perfectly with our vision to innovate and provide accessible mobile charging solutions to a diverse range of users, particularly in the transit and gaming sectors, as well as in healthcare." This acquisition signifies more than just a merger of two innovative companies; it represents a strategic move to connect brands and advertising, offering unprecedented opportunities for businesses to engage with consumers through the widespread deployment of mobile charging solutions in high-traffic areas, including healthcare facilities. The combined strengths of FUZE Technology and MobileQubes will undoubtedly drive future innovation and redefine the landscape of out-of-home mobile charging, encompassing various sectors, including healthcare. FUZE Technology looks forward to a future of enhanced offerings and expanded reach, continuing to revolutionize the way people stay charged on the go. Contact Details Charge Fuze Press press@chargefuze.com

October 25, 2023 09:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

National Survey Reveals Women of All Ages Cite Mental Health as Their Number One Health Concern

LevLane

LevLane Advertising, an award-winning full-service agency headquartered in Philadelphia, has released the results of its 2023 Women’s Health Concerns Survey of 400 women, ages 18+, which explores how women are approaching various aspects of their health and wellness. The survey, which was conducted by a market research provider on behalf of LevLane, paints a concerning picture, as women report deprioritizing sexual/reproductive health and almost every other aspect of their well-being, while mental health concerns take priority. This is true even in the younger age groups where sexual health is traditionally considered as a primary concern (ages 18-34). Across all ages 18+, just 6% of all women reported sexual health as their number one priority. The majority of women (53%) reported mental health as one of their top three health concerns, with 26% saying that it was their number one concern. Stress management (45%), sleep health (33%) and heart health (32%) were among the other top concerns, while reproductive/sexual health (19%), diabetes (18%), pregnancy/post-partum (11%) and menopause/perimenopause (11%) were ranked lowest overall. Women 55+ were the only age group to report something other than mental health as their top concern. That cohort reported both heart health and stress management as tied for their number one priority. “Coming out of COVID, we expected to see a bump in mental health as a concern, but we were all taken aback by just how many women across all age groups cited it as their top concern,” said Liz Weir, chief marketing officer at LevLane. “Even in younger age groups, where we would expect to see more of an emphasis on sexual and reproductive health or pregnancy and post-partum, we found that women are putting those things on the back burner to prioritize mental health.” The study is the first in a series planned by the agency. The forthcoming surveys will continue to focus on specific aspects of women’s health with the goal of better understanding the broader women’s healthcare landscape. “In their efforts to address mental health concerns, an unintended consequence could be neglecting other very critical aspects of their well-being,” said Karla Loken, DO, OBGYN, FACOOG and chief medical officer for FEMSelect. “We need to address women’s health comprehensively; neglecting one area will ultimately lead to consequences in another. Women are juggling a lot of things, and this research is signaling that women need more support, including education and awareness on promoting a balanced approach to physical, mental and emotional health.” The study also found that many women are opting out of support, with half (50%) of the respondents saying they are not seeking support for their top concern/priority and have no intention of doing so. Additional Survey Findings: - 10% of Women 18-24 reported sexual and reproductive health as a top priority - 35% of women 35-44 said mental health was their top priority - Women 18-24 were the age group most concerned with cancer as a top 3 priority - Women 35-44 were the only age group to include obesity as a top 3 priority or concern - Women in the 18-34 bracket tend to start their health journeys with online search or through friends and family - Women 34+ tend to start their health journeys with their primary care physicians (PCPs) For complete survey results, please contact Lauren Stralo below. About LevLane LevLane Advertising is a full-service independent advertising agency headquartered in Philadelphia and has been building brands people love for nearly 40 years. The award-winning agency integrates traditional creative expertise with cutting-edge digital capabilities in its menu of services, including search engine optimization (SEO), search engine marketing (SEM), programmatic media, strategy, creative and branding, media and analytics, social media, content marketing, and public relations. For more information about LevLane and its capabilities, connect with us on LinkedIn, Instagram and Facebook. Contact Details LevLane Advertising Lauren Stralo +1 484-747-0172 lweir@levlane.com Company Website https://www.levlane.com

October 24, 2023 10:00 AM Eastern Daylight Time

Image
1 ... 6768697071 ... 250